Ordóñez-Navadijo, Á <br/><br/>
Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.  [electronic resource] 

 -  Oncogene  Feb 2016 
 - 587-94 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2015.113  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Neoplasm--genetics<br/>Carcinoma, Renal Cell--genetics<br/>Cell Hypoxia--genetics<br/>Cell Line, Tumor<br/>Cell Proliferation--genetics<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--genetics<br/>Kidney Neoplasms--genetics<br/>Ribonucleoproteins, Small Nuclear--genetics<br/>Von Hippel-Lindau Tumor Suppressor Protein--genetics